{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:20:23Z","timestamp":1781360423437,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00592-020-01496-7","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T07:02:31Z","timestamp":1582959751000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-7311","authenticated-orcid":false,"given":"Mariacristina","family":"Parravano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"1496_CR1","first-page":"CD007419","volume":"10","author":"G Virgili","year":"2014","unstructured":"Virgili G, Parravano M, Menchini F, Evans JR (2014) Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 10:CD007419","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1496_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR et al (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136(3):257\u2013269","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1496_CR3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6):1064\u20131077.e35","journal-title":"Ophthalmology"},{"issue":"4","key":"1496_CR4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789\u2013801","journal-title":"Ophthalmology"},{"issue":"3","key":"1496_CR5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","volume":"114","author":"DJ Browning","year":"2007","unstructured":"Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR et al (2007) Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114(3):525\u2013536","journal-title":"Ophthalmology"},{"issue":"13","key":"1496_CR6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193\u20131203","journal-title":"N Engl J Med"},{"key":"1496_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.1963","author":"NM Bressler","year":"2019","unstructured":"Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK, DRCR Retina Network (2019) Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.1963","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"1496_CR8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archopht.126.12.1707","volume":"126","author":"NH White","year":"2008","unstructured":"White NH, Sun W, Cleary PA et al (2008) Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10\u00a0years after the diabetes control and complications trial. Arch Ophthalmol 126(12):1707\u20131715","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"1496_CR9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ophtha.2016.03.038","volume":"123","author":"RP Singh","year":"2016","unstructured":"Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I (2016) The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology 123(7):1581\u20131587","journal-title":"Ophthalmology"},{"issue":"10","key":"1496_CR10","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122(10):2044\u20132052","journal-title":"Ophthalmology"},{"issue":"4","key":"1496_CR11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","volume":"137","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG et al (2019) Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol 137(4):382\u2013389","journal-title":"JAMA Ophthalmol"},{"key":"1496_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.visres.2017.06.015","volume":"139","author":"EA Urias","year":"2017","unstructured":"Urias EA, Urias GA, Monickaraj F, McGuire P, Das A (2017) Novel therapeutic targets in diabetic macular edema: beyond VEGF. Vis Res 139:221\u2013227","journal-title":"Vis Res"},{"key":"1496_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000455265","volume":"58","author":"J Cunha-Vaz","year":"2017","unstructured":"Cunha-Vaz J (2017) Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown. Dev Ophthalmol 58:11\u201320","journal-title":"Dev Ophthalmol"},{"issue":"1","key":"1496_CR14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2017.5202","volume":"136","author":"YT Hsieh","year":"2018","unstructured":"Hsieh YT, Tsai MJ, Tu ST, Hsieh MC (2018) Association of abnormal renal profiles and proliferative diabetic retinopathy and diabetic macular edema in an Asian population with type 2 diabetes. JAMA Ophthalmol 136(1):68\u201374","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1496_CR15","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1167\/iovs.19-26749","volume":"60","author":"M Yamamoto","year":"2019","unstructured":"Yamamoto M, Fujihara K, Ishizawa M et al (2019) Overt proteinuria, moderately reduced eGFR and their combination are predictive of severe diabetic retinopathy or diabetic macular edema in diabetes. Invest Ophthalmol Vis Sci 60(7):2685\u20132689","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"1496_CR16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3928\/23258160-20170928-09","volume":"48","author":"SS Ong","year":"2017","unstructured":"Ong SS, Thomas AS, Fekrat S (2017) Improvement of recalcitrant diabetic macular edema after peritoneal dialysis. Ophthalmic Surg Lasers Imaging Retina 48(10):834\u2013837","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"1496_CR17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/jdi.12771","volume":"9","author":"Y Kameda","year":"2018","unstructured":"Kameda Y, Babazono T, Uchigata Y, Kitano S (2018) Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig 9(4):937\u2013939","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1496_CR18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","volume":"134","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Ayala AR, Bressler NM et al (2016) Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134(3):278\u2013285","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1496_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2017.06.029","volume":"125","author":"DS Dhoot","year":"2018","unstructured":"Dhoot DS, Baker K, Saroj N, Vitti R, Berliner AJ, Metzig C, Thompson D, Singh RP (2018) Baseline factors affecting changes in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema: post hoc analyses from VISTA and VIVID. Ophthalmology 125(1):51\u201356","journal-title":"Ophthalmology"},{"key":"1496_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM et al (2016) early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172:72\u201379","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1496_CR21","doi-asserted-by":"crossref","first-page":"e0159553","DOI":"10.1371\/journal.pone.0159553","volume":"11","author":"L Zhang","year":"2016","unstructured":"Zhang L, Wang W, Gao Y, Lan J, Xie L (2016) The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network meta-analysis. PLoS ONE 11(7):e0159553","journal-title":"PLoS ONE"},{"issue":"10","key":"1496_CR22","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1167\/iovs.12-9692","volume":"53","author":"G Querques","year":"2012","unstructured":"Querques G, Lattanzio R, Querques L et al (2012) Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci 53(10):6017\u20136024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1496_CR23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2014.09.033","volume":"159","author":"N Rayess","year":"2015","unstructured":"Rayess N, Rahimy E, Ying GS et al (2015) Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 159(1):85\u201391","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1496_CR24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/bjophthalmol-2017-310664","volume":"102","author":"G Staurenghi","year":"2018","unstructured":"Staurenghi G, Feltgen N, Arnold JJ et al (2018) Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol 102(7):954\u2013958","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1496_CR25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/IAE.0000000000002422","volume":"39","author":"S Bonnin","year":"2019","unstructured":"Bonnin S, Dupas B, Lavia C et al (2019) Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina 39(3):426\u2013434","journal-title":"Retina"},{"issue":"12","key":"1496_CR26","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.ophtha.2019.06.022","volume":"126","author":"A Couturier","year":"2019","unstructured":"Couturier A, Rey PA, Erginay A, Lavia C, Bonnin S, Dupas B, Gaudric A, Tadayoni R (2019) Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology 126(12):1685\u20131694. https:\/\/doi.org\/10.1016\/j.ophtha.2019.06.022","journal-title":"Ophthalmology"},{"issue":"2","key":"1496_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jamaophthalmol.2016.4820","volume":"135","author":"FL Ferris","year":"2017","unstructured":"Ferris FL, Maguire MG, Glassman AR, Ying GS, Martin DF (2017) Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol 135(2):145\u2013149","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1496_CR28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2016.02.007","volume":"123","author":"DJ Pieramici","year":"2016","unstructured":"Pieramici DJ, Wang PW, Ding B, Gune S (2016) Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in RIDE and RISE. Ophthalmology 123(6):1345\u20131350","journal-title":"Ophthalmology"},{"key":"1496_CR29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2015.12.030","volume":"164","author":"E Rahimy","year":"2016","unstructured":"Rahimy E, Shahlaee A, Khan MA et al (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118\u2013127","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1496_CR30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00417-017-3836-1","volume":"256","author":"R Laiginhas","year":"2018","unstructured":"Laiginhas R, Silva MI, Rosas V et al (2018) Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol 256(1):83\u201389","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1496_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","volume":"136","author":"RK Maturi","year":"2018","unstructured":"Maturi RK, Glassman AR, Liu D et al (2018) Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol 136(1):29\u201338","journal-title":"JAMA Ophthalmol"},{"key":"1496_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119848257","author":"A Hern\u00e1ndez Mart\u00ednez","year":"2019","unstructured":"Hern\u00e1ndez Mart\u00ednez A, Pereira Delgado E, Silva Silva G, Castellanos Mateos L, Lorente Pascual J, Lainez Villa J, Garc\u00eda Vicente P, Almeida-Gonz\u00e1lez CV (2019) Early versus late switch: how long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients? Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/1120672119848257","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"1496_CR33","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/bjophthalmol-2017-310242","volume":"101","author":"MV Cicinelli","year":"2017","unstructured":"Cicinelli MV, Cavalleri M, Querques L, Rabiolo A, Bandello F, Querques G (2017) Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol 101(12):1689\u20131693","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1496_CR34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00592-019-01416-4","volume":"56","author":"C Busch","year":"2019","unstructured":"Busch C, Fraser-Bell S, Iglicki M et al (2019) Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol 56(12):1341\u20131350","journal-title":"Acta Diabetol"},{"issue":"3","key":"1496_CR35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/IAE.0000000000000770","volume":"36","author":"KH Seo","year":"2016","unstructured":"Seo KH, Yu SY, Kim M, Kwak HW (2016) Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina 36(3):588\u2013595","journal-title":"Retina"},{"key":"1496_CR36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ajo.2017.06.026","volume":"181","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic S, Torresin T, Berton M, Bini S, Convento E, Midena E (2017) Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am J Ophthalmol 181:149\u2013155","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1496_CR37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/aos.13294","volume":"95","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic S, Torresin T, Bini S et al (2017) Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol 95(5):464\u2013471","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1496_CR38","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/IAE.0000000000001304","volume":"37","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic S, Bini S, Torresin T et al (2017) Hyperreflective retinal spots in normal and diabetic eyes: B-scan and en face spectral domain optical coherence tomography evaluation. Retina 37(6):1092\u20131103","journal-title":"Retina"},{"issue":"7","key":"1496_CR39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/IAE.0000000000000912","volume":"36","author":"S Vujosevic","year":"2016","unstructured":"Vujosevic S, Berton M, Bini S, Casciano M, Cavarzeran F, Midena E (2016) Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema. Retina 36(7):1298\u20131308","journal-title":"Retina"},{"issue":"10","key":"1496_CR40","doi-asserted-by":"crossref","first-page":"e0206482","DOI":"10.1371\/journal.pone.0206482","volume":"13","author":"V Schreur","year":"2018","unstructured":"Schreur V, Altay L, van Asten F et al (2018) Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS ONE 13(10):e0206482","journal-title":"PLoS ONE"},{"issue":"1","key":"1496_CR41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2010.01.039","volume":"150","author":"AS Maheshwary","year":"2010","unstructured":"Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR (2010) The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol 150(1):63\u201367","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1496_CR42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.oret.2017.07.003","volume":"2","author":"BG Moon","year":"2018","unstructured":"Moon BG, Um T, Lee J, Yoon YH (2018) Correlation between deep capillary plexus perfusion and long-term photoreceptor recovery after diabetic macular edema treatment. Ophthalmol Retina 2(3):235\u2013243","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"1496_CR43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun JK, Lin MM, Lammer J et al (2014) Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132(11):1309\u20131316","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1496_CR44","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","volume":"38","author":"AR Santos","year":"2018","unstructured":"Santos AR, Costa M\u00c2, Schwartz C et al (2018) Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the CHARTRES study. Retina 38(6):1110\u20131119","journal-title":"Retina"},{"issue":"2","key":"1496_CR45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","volume":"125","author":"D Zur","year":"2018","unstructured":"Zur D, Iglicki M, Busch C et al (2018) OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 125(2):267\u2013275","journal-title":"Ophthalmology"},{"issue":"2","key":"1496_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00592-019-01389-4","volume":"57","author":"M Cavalleri","year":"2019","unstructured":"Cavalleri M, Cicinelli MV, Parravano M, Varano M, De Geronimo D, Sacconi R, Bandello F, Querques G (2019) Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. Acta Diabetol 57(2):163\u2013171. https:\/\/doi.org\/10.1007\/s00592-019-01389-4","journal-title":"Acta Diabetol"},{"issue":"12","key":"1496_CR47","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","volume":"100","author":"M Ashraf","year":"2016","unstructured":"Ashraf M, Souka A, Adelman R (2016) Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol 100(12):1596\u20131604","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1496_CR48","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1097\/IAE.0000000000000859","volume":"35","author":"A Couturier","year":"2015","unstructured":"Couturier A, Man\u00e9 V, Bonnin S et al (2015) Capillary plexus anomalies in diabetic retinopathy on optical coherence tomography angiography. Retina 35(11):2384\u20132391","journal-title":"Retina"},{"issue":"11","key":"1496_CR49","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ophtha.2016.07.010","volume":"123","author":"J Lee","year":"2016","unstructured":"Lee J, Moon BG, Cho AR, Yoon YH (2016) Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology 123(11):2368\u20132375","journal-title":"Ophthalmology"},{"key":"1496_CR50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajo.2016.05.002","volume":"168","author":"F Scarinci","year":"2016","unstructured":"Scarinci F, Nesper PL, Fawzi AA (2016) Deep retinal capillary nonperfusion is associated with photoreceptor disruption in diabetic macular ischemia. Am J Ophthalmol 168:129\u2013138","journal-title":"Am J Ophthalmol"},{"key":"1496_CR51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2017.04.021","volume":"179","author":"M Parravano","year":"2017","unstructured":"Parravano M, De Geronimo D, Scarinci F et al (2017) Diabetic microaneurysms internal reflectivity on spectral-domain optical coherence tomography and optical coherence tomography angiography detection. Am J Ophthalmol 179:90\u201396","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"1496_CR52","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.ophtha.2016.07.008","volume":"123","author":"C Balaratnasingam","year":"2016","unstructured":"Balaratnasingam C, Inoue M, Ahn S et al (2016) Visual acuity is correlated with the area of the foveal avascular zone in diabetic retinopathy and retinal vein occlusion. Ophthalmology 123(11):2352\u20132367","journal-title":"Ophthalmology"},{"issue":"10","key":"1496_CR53","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.oret.2019.04.027","volume":"3","author":"YT Hsieh","year":"2019","unstructured":"Hsieh YT, Alam MN, Le D, Hsiao CC, Yang CH, Chao DL, Yao X (2019) OCT angiography biomarkers for predicting visual outcomes after ranibizumab treatment for diabetic macular edema. Ophthalmol Retina 3(10):826\u2013834. https:\/\/doi.org\/10.1016\/j.oret.2019.04.027","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1496_CR54","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41598-018-38248-1","volume":"9","author":"C Busch","year":"2019","unstructured":"Busch C, Wakabayashi T, Sato T et al (2019) Retinal microvasculature and visual acuity after intravitreal aflibercept in diabetic macular edema: an optical coherence tomography angiography study. Sci Rep 9(1):1561","journal-title":"Sci Rep"},{"issue":"6","key":"1496_CR55","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/ijms18061181","volume":"18","author":"L Toto","year":"2017","unstructured":"Toto L, D\u2019Aloisio R, Di Nicola M et al (2017) Qualitative and quantitative assessment of vascular changes in diabetic macular edema after dexamethasone implant using optical coherence tomography angiography. Int J Mol Sci 18(6):1181","journal-title":"Int J Mol Sci"},{"key":"1496_CR56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajo.2019.04.002","volume":"206","author":"T Felfeli","year":"2019","unstructured":"Felfeli T, Juncal VR, Hillier RJ, Mak MYK, Wong DT, Berger AR, Kohly RP, Kertes PJ, Eng KT, Boyd SR, Altomare F, Giavedoni LR, Muni RH (2019) Aqueous humor cytokines and long-term response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 206:176\u2013183. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.002","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1496_CR57","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1167\/iovs.18-26215","volume":"60","author":"M Figueras-Roca","year":"2019","unstructured":"Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J et al (2019) Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Invest Ophthalmol Vis Sci 60(5):1336\u20131343","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-020-01496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-020-01496-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-020-01496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:23:40Z","timestamp":1614471820000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-020-01496-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1007\/s00592-020-01496-7","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,29]]},"assertion":[{"value":"18 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mariacristina Parravano has the following disclosures: Allergan (S), Bayer (S); Novartis (S). Eliana Costanzo has nothing to disclose. Giuseppe Querques has the following disclosures: Allergan (S), Alimera (S), Amgen (S), Bayer (S), KHB (S), Novartis (S), Roche (S), Sandoz (S), Zeiss (S); Allergan (C), Alimera (C), Bausch and Lomb (C), Bayer (C), Heidelberg (C), Novartis (C), Zeiss (C).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this review no ethical standard statement was applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this review no informed consent was applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}